DoW Toxic Exposures Investigator Initiated Research Award
Summary: The fiscal year 2026 Toxic Exposures Research Program (TERP) Investigator-Initiated Research Award (IIRA) is intended to support studies that will make an important contribution toward research and/or patient care for diseases or conditions associated with military-related toxic exposures. Offered by Defense Health Agency Contracting Activity - DHACA; awards $2.4M; applications due November 19, 2026.
Key Facts
- Funder
- Defense Health Agency Contracting Activity - DHACA
- Award amount
- $2.4M
- Deadline
- November 19, 2026
- Geography
- United States
- Categories
- Research
- Status
- Open
About This Grant
Summary: The fiscal year 2026 Toxic Exposures Research Program (TERP) Investigator-Initiated Research Award (IIRA) is intended to support studies that will make an important contribution toward research and/or patient care for diseases or conditions associated with military-related toxic exposures. Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as...
Full requirements and application instructions: official listing.
Similar Open Grants
DoW Neurofibromatosis Investigator-Initiated Research Award
Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Research Academy – Scholar Award
Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Exploration-Hypothesis Development Award
Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
Defense Health Agency Contracting Activity - DHACA
DoW Duchenne Muscular Dystrophy, Clinical/Translational Research Award
Defense Health Agency Contracting Activity - DHACA
DOW Combat Readiness – Medical Research Program Translational Research Award
Defense Health Agency Contracting Activity - DHACA
DoW Toxic Exposures Translational Research Award
Defense Health Agency Contracting Activity - DHACA
NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
National Institutes of Health
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
National Institutes of Health
HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)
National Institutes of Health